Abstract
The current treatment of pituitary adenomas requires a balance of conservative management, surgical resection, and in select tumor types, molecular therapy. Acromegaly treatment is an evolving field where our understanding of molecular targets and drug therapies has improved treatment options for patients with excess growth hormone levels. We highlight the use of molecular therapies in this disease process and advances in this field, which may represent a paradigm shift for the future of pituitary adenoma treatment.
Highlights
Pituitary adenomas make up more than 90% of all pituitary tumors and are the second most commonly diagnosed non-malignant brain tumors [1]
Surgical resection remains the mainstay of therapy for macroadenomas causing compression of neurovascular structures, as well as for many functional microadenomas, pharmacotherapy can play a crucial role in adenoma treatment
Recent advances in genetic and molecular analysis of pituitary adenomas have provided new insights into the growth patterns and secretory functions of these tumors and have allowed for a more precise characterization of individual adenomas. These advances have led to the development of targeted molecular therapies for several subtypes of pituitary adenoma and the development of a Abbreviations: Adrenocorticotropic hormone (ACTH), adrenocorticotropic hormone; DR, dopamine receptor; GH, growth hormone; IGF, insulin-like growth factor; OGTT, oral glucose tolerance test
Summary
The current treatment of pituitary adenomas requires a balance of conservative management, surgical resection, and in select tumor types, molecular therapy. Treatment is an evolving field where our understanding of molecular targets and drug therapies has improved treatment options for patients with excess growth hormone levels. We highlight the use of molecular therapies in this disease process and advances in this field, which may represent a paradigm shift for the future of pituitary adenoma treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
